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Abstract
We report a method for production of soluble heparin binding domain (HBD) of human vascular endothelial growth factor
VEGF-A165. Recombinant VEGF-A165-HBD that contains four disulphide bridges was expressed in specialised E. coli SHuffle
cells and its activity has been confirmed through interactions with neuropilin and heparin. The ability to produce significant
quantities of a soluble active form of VEGF-A165-HBD will enable further studies addressing the role of VEGF-A in essential
processes such as angiogenesis, vasculogenesis and vascular permeability.
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Introduction
Vascular endothelial growth factor-A (VEGF-A), plays essential
roles in vascular development in embryogenesis, in the mainte-
nance of the normal function of the adult vasculature and in
neovascularisation associated with cancer, eye and other diseases
[1]. VEGF-A elicits cellular responses through binding to the
receptor tyrosine kinases, VEGFR1 and VEGFR2 [1]. In
addition, VEGF-A interacts with neuropilins (NRP) 1 and 2,
transmembrane proteins that function as co-receptors to VEGFRs
[2], [3].
VEGF-A is expressed in multiple isoforms (i.e. VEGF-A121,
VEGF-A145, VEGF-A165, VEGF165b, VEGF-A189, and VEGF-
A206) that are generated through alternative mRNA splicing of
a single VEGF-A gene transcript containing 8 exons [4], [5], [6].
VEGF-A165 is the most abundant and biologically active isoform
that is able to bind VEGFR1, VEGFR2, NRP1 and NRP2.
VEGF-A165 also binds heparin and heparan sulfate, a property
shared by VEGF-A189 and VEGF-A206 isoforms which are not
diffusible and are thought to remain tightly associated with the cell
surface or extracellular matrix [7]. All of these isoforms contain the
50 residues-long C-terminal protein region encoded by exons 7
and 8 that was identified as a ‘heparin-binding domain’ (HBD) [7].
In contrast, VEGF-A121, an isoform that does not include exon 7,
does not bind to heparin and is freely diffusible. VEGF-A is
a dimeric molecule, with each polypeptide chain containing
multiple intrachain disulphide bonds forming a cysteine knot
motif. Although, several structures of VEGF interacting with
VEGFR extracellular Ig-like domains 2 and 3 have been reported,
including the structure of a VEGF-A/VEGFR2 complex [8], none
of these contains the heparin binding domain of VEGF. The
structure of the C-terminal 55 residues of VEGF-A165 has been
determined by solution NMR spectroscopy [9]. In that study the
protein fragment that was generated by plasmin digestion of the
refolded full-length VEGF-A165 includes additional 5 amino acids
preceding HBD. The domain is very basic, with pI of ,11, shares
no sequence or structure homology to other known proteins and
comprises two b-sheet subdomains, each containing two dis-
ulphide bridges. Molecular dynamics simulation and the NMR
studies examining dynamic properties of the isolated HBD showed
that the N-terminal region exhibited greater flexibility compared
to the C-terminal subdomain [10], [11].
While heparin binding domain does not appear to bind to the
soluble VEGF receptors [7], HBD binds to NRP and is required
for VEGF-A165 interaction with NRP, either independently or
when in a complex with NRP and VEGF receptors where VEGF-
A165 bridges between VEGFR2 and NRP. It was shown that the
C-terminal region of VEGF-A165 is critical for its mitogenic
potency and it was postulated that its removal by plasmin activity
might result in a weakening of the angiogenic signal further away
from the site of VEGF synthesis [7]. However, very little is known
about the activity of the plasmin released HBD. In NRP, the
region comprising tandem coagulation factor V/VIII type
domains b1 and b2 specifically interacts with the C-terminus of
VEGF-A165 with the b1 domain of NRP playing the most
important role in VEGF-A binding [12], [13]. In addition to
interacting with VEGFs, NRPs bind to the class 3 semaphorin
family of axon guidance molecules (SEMAs), unrelated to VEGFs.
By signalling in response to these two families of ligands, NRPs
play essential roles in embryonic blood vessel development and
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neuronal patterning. NRPs are also implicated in the pathogenesis
of cancer and other diseases [14], [15].
A full understanding of the signaling properties, specificity and
molecular basis of VEGF/NRP/VEGFR2 interactions has been
hampered by an inability to easily produce a soluble VEGF-A
HBD domain. To date, the production of soluble VEGF-A165 in
E. coli involved denaturation, refolding and extensive purification
from the insoluble protein fraction [9]. Refolded full-length
VEGF-A165 has subsequently been used to generate the HBD
through plasmin proteolytic cleavage [7], [9], [16]. A smaller C-
terminal domain (CTD) region of VEGF-A165, has been previously
chemically synthesized [10], [17]. The NRP1 b1 domain has also
been co-crystallised with a small molecule antagonist of the VEGF
interaction with NRP1 [17]. Most recently, an attempt to gain an
insight into the NRP/VEGF interaction was made by generating
a fusion of the NRP1 b1 and VEGF-A165-HBD domains and
determining the crystal structure of this chimerical protein
construct [18]. While the structure of this fusion protein might
provide some additional information, caution should be exercised
in interpretation of specific points of interaction inferred from this
structure as these are restricted by the artificial covalent
attachment between the two domains.
Here we report a new method that overcomes the need to use
refolding of an insoluble VEGF-A165 protein to obtain soluble
VEGF-A165-HBD. The availability of soluble biologically active
VEGF-A HBD will be invaluable for future structural elucidation
of the interaction between VEGF-A and NRPs and will enable
further studies addressing physiological role of HBD.
Materials and Methods
Expression and Purification of VEGF-A165-HBD
The gene sequence corresponding to the 50 residue-long HBD of
VEGF-A165 encoded by exons 7 and 8was adapted to the genome of
E. coli K12 and synthesised by Eurofins (for details see below). The
restriction enzyme sequences of NdeI (CATATG) and XhoI
(CTCGAG) were incorporated into the 59 and 39 sites of the gene,
respectively.The synthesized genewas then sub-cloned intopET14b
(Novagen).TherecombinantpET14b:VEGF-A165-HBDexpression
construct was confirmed by DNA sequencing (Eurofins) and
transformedintoRosetta-gami2(DE3)pLysScells (EMDChemicals,
#71403-3) and SHuffle cells (New England Biolabs, #C3029H).
Tetracycline was used when growing Rosetta-gami 2 (DE3) pLysS
cells in order to select only for mutations in thioredoxin reductase
(trxB) and glutathione reductase (gor) genes that enhance disulphide
bond formation in the cytoplasm [19]. Since only the features of the
Origami 2 strain was selected from the Rosetta-gami 2 (DE3) pLysS
cells, the cells used in producing VEGF-A165-HBD are referred to as
Origami 2 cells. SHuffle cells were used as they are E. coli B cells
engineered to form disulphide bonded proteins in the cytoplasm
through theexpressionofachromosomalcopyof thedisulphidebond
isomerase DsbC that promotes the correction of mis-oxidized
proteins into their correct form [19], [20]. In both cases, 10 ml
overnight cultures were transferred into 1 liter lysogeny brothmedia
(LB) and cells were grown at 37uC until absorbance at 600 nm
reached 0.6. The cells were then induced with isopropyl-b-D-thio-
galactoside (IPTG) at a final concentration of 0.5 mM and left
overnight at 30uC. Cells were then centrifuged at 4,000 rpm for 15
minutes inaBeckmanCoulterAvantiJ-26XPcentrifuge(usingaJLA-
8.1000 rotor) and resuspended in buffer A consisting of 50 mMTris
pH 7.9, 30 mMimidazole and300 mMNaCl.The cellswere frozen
at 220uC and subsequently thawed and sonicated. The soluble
protein was separated from the insoluble fraction through centrifu-
gation at 18,000 rpm for 30 minutes in a Sorvall RC 5B Plus
centrifuge (using a SS-34 rotor). The soluble VEGF-A165-HBD was
then purified via its hexahistidine tag (His6-tag) on a nickel chelating
affinity column (GE Healthcare, #17-5248-02) attached to an
AKTA prime FPLC instrument (GEHealthcare) using a gradient of
0–100% (v/v) buffer B consisting of 50 mM Tris pH 7.9, 600 mM
imidazole and 300 mM NaCl. The fractions containing purified
VEGF-A165-HBD were ultimately confirmed by SDS-PAGE anal-
ysis as the weak absorbance of VEGF-A165-HBD at 280 nm was
masked by increasing amounts of imidazole. Biorad protein assay
solution (Biorad, #500-0006) was initially used to decide which
fractionscontainedelutedprotein (1 mlofBioradsolutionwasdiluted
in a total volume of 5 ml and then aliquots of 50 ml were mixed with
20 ml of protein sample).Aquick visible changeof colour frombrown
to blue was used to detect presence of protein in the fractions using
Biorad solution. VEGF-A165-HBD was further purified on a pre-
parative HiLoad 16/60 Superdex 75 size exclusion column (GE
Healthcare,#17-5174-01). The protein yield from a litre of culture
was estimated to be 5 mg (1 mg ofVEGF-A165-HBD from every g of
SHuffle cell pellet). His6-tag of VEGF-A165-HBDwas removed with
thrombin (Novagen, #69671) in a cleavage buffer consisting of
20 mM Tris pH 8.4, 150 mM NaCl and 2.5 mM CaCl2. To every
mgofprotein, 1 ml of thrombin (1unit/ml)wasaddedand themixture
was dialysed overnight at room temperature using a Float-A-Lyzer
G2 dialysis tube with MWCO of 0.5–1 kDa (Spectra/Por,
#G235051). Thrombin was removed either by filtration or by
passing theproteinmixtureover theheparincolumn.Purifiedprotein
is stored at220uC.
Gene Encoding VEGF-A165 -HBD
Original sequence:
CCC TGT GGG CCT TGC TCA GAG CGG AGA AAG
CAT TTG TTT GTA CAA GAT CCG CAG ACG TGT AAA
TGT TCC TGC AAA AAC ACA GAC TCG CGT TGC AAG
GCG AGG CAG CTT GAG TTA AAC GAA CGT ACT TGC
AGA TGT GAC AAG CCG AGG CGG TGA.
Adapted sequence and restriction enzyme sites (in bold):
59 CATATG CCG TGT GGC CCA TGT TCG GAA CGT
CGC AAA CAT CTG TTT GTG CAG GAT CCG CAA ACG
TGC AAA TGC AGC TGC AAG AAC ACC GAT AGT CGC
TGC AAA GCG CGT CAG TTA GAG CTG AAT GAA CGG
ACT TGT CGC TGT GAC AAA CCT CGT CGC TAA
CTCGAG 39.
Binding of VEGF-A165-HBD to Heparin Column
VEGF-A165-HBD was shown to bind to heparin using a heparin
column (GE Healthcare- 5 ml column, 17-0407-01) and eluted at
a concentration of 500 mM NaCl. The Heparin column had
covalently bound heparin, a naturally occurring sulphated glucosa-
minoglycan that is extracted from the native proteoglycan of porcine
intestinal mucosa, with alternating units of uronic acid and D-
glucosamine, most of which are substituted with one or two sulphate
groups.
Binding of VEGF-A165-HBD to NRP in a Cell Based Assay
Binding displacement experiments were carried out using
human prostate cancer cell line DU145 as previously described
[17], [21]. 96-well plates were pre-coated with PDL (Poly-D-
Lysine) for one hour and washed three times with distilled water.
DU145 cells were plated at 26104 per well in 0.1 ml medium and
after four hours, were infected with NRP1 adenovirus (Ad.NRP1).
The binding assay was performed 48 hours after adenoviral
infection by the addition of various concentrations of either
VEGF-A165 (R&D Systems) (positive control) or VEGF-A165-HBD
diluted in binding medium with or without 0.1% bovine serum
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PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e55690
albumin (BSA), followed by addition of 1 nM biotinylated (bt)
VEGF-A165 (R&D Systems). DU145 cells used in these assays do
not express other VEGF receptors [21] and the levels of
endogenously expressed NRP1 are too low to reliably measure
binding of bt-VEGF-A165 to endogenous NRP1. After 2 h of
incubation at room temperature, the plates were washed three
times with phosphate buffered saline (PBS). The bt-VEGF-A165
bound to Ad.NRP1 was detected by incubation with streptavidin-
horseradish peroxidase conjugates for 30 min. Cells were then
washed 3 times in PBS before detection with substrate reagent
(R&D Systems) for 20 min. The reaction was stopped with
stopping solutions and signal intensity quantified using a Tecan
Genios plate reader at A450 nm with a reference wavelength of
595 nm. Nonspecific binding was determined in the presence of
100-fold excess of unlabelled VEGF-A165.
Binding Assay of VEGF-A165-HBD to NRP Using Size
Exclusion Chromatography
VEGF-AVEGF-A165-HBD binds to NRP in solution as
demonstrated by both a preparative HiLoad 16/60 Superdex 75
size exclusion chromatography column (GE Healthcare, #17-
Figure 1. Steps to producing soluble VEGF-A165-HBD. The gene sequence encoding the VEGF-A165-HBD protein was adapted to that of E. coli
K12 genome and the 59 and 39 restriction enzyme sequences of NdeI and XhoI were incorporated, respectively. The gene was then synthesised and
subcloned into pET14b by Eurofins. The recombinant plasmid was transformed into Origami 2 and SHuffle cells and tested for expression. (a) VEGF-
A165-HBD was over-produced and purified from both cell types; however, VEGF-A165-HBD produced from SHuffle cells showed a greater yield of
presumably folded protein based on absorbance at 280 nm which was solely dependent on cysteines having formed cystines (disulphide bonds).
Even though relative staining of the protein bands on the gel would suggest that the two protein samples are at similar concentrations, absorbance
measurements at 280 nm indicate that the sample from SHuffle cells had a concentration of 3.1 mg/ml of disulphide-bonds-containing protein
compared to 1.7 mg/ml in Origami cells. (b) VEGF-A165-HBD protein from SHuffle cells was further purified on a preparative Superdex 75 size
exclusion column. (c) His6-tag was successfully removed using thrombin and resulting VEGF-A165-HBD retained solubility and stability as assessed by
absence of precipitation and further proteolytic cleavage.
doi:10.1371/journal.pone.0055690.g001
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5174-01) and an analytical Superdex 75 pc 3.2/30 size exclusion
column (GE Healthcare, #17-0771-01). This observation is also
not dependent on presence of the N-terminal affinity tag. Binding
of NRP1 and NRP2 b1 domains to VEGF-A165-HBD was assessed
by mixing a tenfold excess of VEGF-A165-HBD with NRP1 and
NRP2 b1 domains (at concentrations of 0.6 mM VEGF-A165-
HBD and 0.06 mM NRP b1). All proteins were purified and
dialysed in buffer consisting of 50 mM Tris pH 7.9 and 100 mM
NaCl prior to mixing. The protein mixtures were incubated at
room temperature for 30 minutes and then loaded onto a pre-
parative Superdex 75 column. The eluted fractions from a single
peak were analysed by SDS-PAGE which revealed the presence of
both VEGF-A165-HBD and NRP1 or NRP2 b1 domains. Further
analysis of VEGF-A165-HBD/NRP interaction was carried out by
using analytical size exclusion chromatography. VEGF-A165-
HBD, NRP b1 and b1b2 domains were purified and dialysed in
buffer consisting of 50 mM Tris pH 7.9 and 100 mM NaCl. To
test the binding of VEGF-A165-HBD to NRP b1 domain, a molar
ratio of 1:10 (NRP: VEGF-A165-HBD) was used and the mixture
incubated at room temperature for an hour. Based on the elution
profiles from the analytical Superdex 75 column it was apparent
that the eluting peak for the mixture had shifted to the left (in
comparison to the NRP b1 peak) indicating that the complex had
formed. A similar approach was taken to test the binding of
VEGF-A165-HBD and NRP b1b2 domain except that the molar
ratio used was 1:28.
Figure 2. Binding of VEGF-A165-HBD to NRP as detected by a cell based assay and size exclusion chromatography. (a) Binding of
VEGF-A165-HBD to NRP1 was determined in DU145 cells expressing an adenoviral construct encoding NRP1 [17]. These cells do not express other
VEGF receptors [21]. Cells were incubated with biotinylated VEGF-A165 in the presence of the indicated concentrations of either unlabelled VEGF-A165
(positive control), or VEGF-A165-HBD containing a His6tag or VEGF-A165-HBD without the tag. Values presented are the means (6SEM) obtained from
two independent experiments. Other experimental details are described in Materials and Methods. (b) Binding of VEGF-A165-HBD to b1 domains of
NRP1 and NRP2 was assessed by size exclusion chromatography. The protein mixtures of a tenfold molar excess of VEGF-A165-HBD with the purified
b1 domain from either NRP1 or NRP2 were incubated at room temperature for 30 minutes. The FPLC profile for VEGF-A165-HBD and NRP1 b1 mixture
is shown. SDS-PAGE analysis was used to evaluate samples of NRP1 b1, VEGF-A165-HBD, and the protein mixture before being loaded onto the size
exclusion column (lanes 1–3, respectively) as well as samples of fractions which eluted from the single peak (lanes 4–6), showing that VEGF-A165-HBD
and NRP1 b1 co-eluted from the preparative Superdex 75 column. A similar result was seen for VEGF-A165-HBD and NRP2 b1. (c) Formation of the
molecular complexes was also investigated by analytical size exclusion chromatography. NRP1 b1 and b1b2 domains as well VEGF-A165-HBD were
initially loaded separately onto the analytical Superdex 75 column and their corresponding FPLC traces are shown in solid and dashed lines,
respectively. To detect binding, NRP1 b1 or b1b2 domains were mixed with VEGF-A165-HBD in solution at a molar ratio of 1:10 and 1:28, respectively
and incubated for an hour at room temperature. The mixtures were then applied to the column. The main peaks in the elution profiles revealed a shift
to the left of the peak positions corresponding to the unbound NRP1 b1 or b1b2 domains (indicated by vertical black lines), suggesting complex
formation.
doi:10.1371/journal.pone.0055690.g002
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Over-expression and Purification of NRP1 and NRP2
Domains Used in this Study
Recombinant pET15b-TEV:nrp1-b1, pET15b-TEV:nrp2-b1
and pET15b-TEV:nrp1-b1b2 constructs were made and gene
sequences confirmed by DNA sequencing (Eurofins). The con-
structs were then transformed into Rosetta-gami 2 (DE3) pLysS
cells (EMD, #71403-3). Tetracyclin and Chloramphenicol were
used when growing Rosetta-gami 2 (DE3) pLysS cells in order to
select for mutations in thioredoxin reductase (trxB) and glutathione
reductase (gor) genes that enhance disulphide bond formation in
the cytoplasm [19] as well as providing seven tRNAs accounting
for the rare codon problem in E. coli [22], [23], [24], [25], [26]. To
over-produce the proteins, 10 ml overnight cultures were trans-
ferred into 1 litre LB media and cells grown at 37uC until
absorbance at 600 nm reached 0.6. The cells were then induced
with IPTG at a final concentration of 0.5 mM and left overnight
at 30uC. Cells were centrifuged at 4,000 rpm for 15 minutes in
a Beckman Coulter Avanti J-26 XP centrifuge (using a JLA-8.1000
rotor) and then resuspended in buffer A consisting of 50 mM Tris
pH 7.9, 30 mM imidazole and 300 mM NaCl. The cells were
then frozen at 220uC and subsequently thawed and sonicated.
The soluble protein was separated from the insoluble fraction
through centrifugation at 18,000 rpm for 30 minutes in a Sorvall
RC 5B Plus centrifuge (using a SS-34 rotor). The soluble proteins
were purified via their His6-tag on a nickel chelating affinity
column (GE Healthcare, #17-5248-02) attached to an AKTA
prime FPLC instrument (GE Healthcare) using a gradient of 0–
100% (v/v) buffer B consisting of 50 mM Tris pH 7.9, 400 mM
imidazole and 300 mM NaCl. To remove the His6-tag from
NRP1 b1, NRP2 b1 and NRP1 b1b2 proteins, fractions eluted
from the nickel chelating column were pooled and the His6-tagged
TEV protease added (1 mg of TEV was used per 8 mg of protein)
in the presence of 0.3 mM L-cysteine and 3 mM L-cystine. The
proteins were then dialysed overnight at 4uC in buffer containing
50 mM Tris pH 7.9, 20 mM imidazole, 300 mM NaCl, 0.3 mM
L-cysteine and 3 mM L-cystine. The dialysed proteins were
subsequently applied to nickel chelating beads in solution to
separate His-cleaved proteins from His6-tagged TEV protease
which bound onto the beads.
Results and Discussion
VEGF-A165-HBD was purified from the soluble cell extracts.
BioRad protein assay reagent, based on the method of Bradford,
as well as sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE) analyses, was used to identify the fractions
containing purified VEGF-A165-HBD. VEGF-A165-HBD contains
no tryptophan or tyrosine residues whose property to absorb light
at 280 nm is commonly used to determine concentration of
proteins in solution. In the case of VEGF-A165-HBD only weak
contribution to absorbance at 280 nm could come from cystines –
cysteine residues oxidized to form disulphide bonds [27]. There
are eight cysteine side chains in the expressed VEGF-A165-HBD
protein and if we were to assume that all four disulphide bridges
were formed in VEGF-A165-HBD, the calculated extinction
coefficient [27] would be 500 M21Lcm21. While the formation
of disulphide bonds is not sufficient evidence that a native-like and
active conformation was generated, we took the appearance of the
disulphide bonds, consistent with the formation of the three-
dimensional structure as the initial measure of folded state of the
produced protein. Thus, when the two protein samples, whose
concentration was determined by a traditional Bradford protein
assay to be equal, exhibited differences in A280 it was interpreted
as if the protein sample with the higher A280 value had a higher
disulphide bond content and higher proportion of folded protein.
Following protein purification by metal ion affinity chromatogra-
phy there was a noticeable difference in absorbance at 280 nm per
unit of the protein concentration for a protein sample generated in
SHuffle cells, compared to the A280 absorbance of an equivalent
concentration (as judged by protein assay and the SDS-PAGE) of
a protein produced in Origami 2 cells. Fig. 1a. shows Coomassie
Blue stained SDS-PAGE gel of the protein samples purified from
the two cell types. Although the two protein bands exhibit similar
levels of staining, the observed absorbance at 280 nm for the two
protein samples suggests that the sample from SHuffle cells with
A280 of 0.2 contained a 3.2 mg/ml of folded protein compared
with an estimated folded protein concentration of 1.6 mg/ml
(A280 = 0.1) in protein sample purified from the Origami 2 cells.
This observation indicated that SHuffle cells were more efficient in
producing higher yields of folded and disulphide-linked VEGF-
A165-HBD. It should be noted that protein bands on the SDS-
PAGE gels occasionally had smeared appearance due to transient
disulphide bonds formation during the electrophoresis.
Even though the presence of disulphide bonds might be
associated with the folding of the polypeptide only the right
pairing of the cysteine residues would give rise to a functionally
active protein structure. Heparin binding of the recombinant
VEGF-A165-HBD was confirmed through interaction with a hep-
arin column; bound protein eluted at 500 mM NaCl. Interesting-
ly, when VEGF-A165-HBD produced from Origami 2 cells was
passed over a heparin column, the resulting eluted protein had
a higher absorbance at 280 nm indicating that heparin binding
facilitated correct disulphide bond formation in VEGF-A165-HBD.
VEGF-A165-HBD protein produced from SHuffle cells was further
purified by size exclusion chromatography (Fig. 1b) and sub-
sequent removal of the His6-tag by thrombin. The resulting
VEGF-A165-HBD remained both soluble and stable in solution
(Fig. 1c). The protein showed no significant signs of degradation or
precipitation after several weeks at 4uC, however we have
routinely stored the purified protein at 220uC.
Crucially, both His6-tagged VEGF-A165-HBD and VEGF-A165-
HBD with the His6-tag removed bind NRP1 in a cell based
binding assay (Fig. 2a) [17]. As it was previously shown that the C-
terminal HBD domain of VEGF-A165 is required for its biological
activity via interaction with NRPs [7] we tested the potential of the
recombinant VEGF-A165-HBD to displace VEGF-A165 from the
surface of DU145 cells. These cells do not express other VEGF
receptors and the binding of VEGF-A165 was due to the presence
of the adenovirully expressed NRP1 [17], [21]. The apparent
binding affinity of VEGF-A165-HBD for NRP1, as judged by
IC50s, was between 100–200 nM which is in agreement with the
previously reported values [17], [28], [29] and it was unaffected by
the presence of BSA in the binding buffer.
Further, we demonstrated binding of VEGF-A165-HBD to
purified recombinant NRP1 b1 and NRP2 b1 domains through
size exclusion chromatography column, as the samples eluted
(from a single peak) contained both proteins (Fig. 2b). Additionally,
experiments using an analytical size exclusion column confirmed
the binding of NRP1 b1 and b1b2 domains to VEGF-A165-HBD
(Fig. 2c). Molecular complex between NRP domains and VEGF-
A165-HBD eluted earlier from the size exclusion column compared
to the elution volumes for the protein peaks of NRP1 b1 and b1b2
domains as well as the elution peak for the free VEGF-A165-HBD
(Fig. 2c). Interaction between NRP and VEGF-A165-HBD was
also observed in affinity chromatography protocols where His6-
tagged NRP1 b1 domain that was bound to the Ni-NTA column
was used to capture un-tagged VEGF-A165-HBD from the
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solution; the two proteins co-eluted upon addition of the
imidazole.
The approach taken in this study to produce soluble VEGF-
A165-HBD can be used to further our understanding of the
interaction between this domain, heparin and NRP receptors. In
particular, it opens the path for carrying out structural, functional
and thermodynamic analyses of complexes with VEGF-A165-HBD
receptors. Characterizations of VEGF-A165-HBD interactions
with its binding partners will ultimately be instrumental in the
development of novel therapeutic molecules targeted to interfere
with these interactions.
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